J&J leads a $25M A round for cancer startup; BMJ frets about Trump’s impact on the scientific community
• J&J Innovation has led a $25 million startup round for Fusion Pharmaceuticals. The Canadian biotech is working on targeted alpha-particle emitting radiotherapeutics which combine “the precision of molecular targeting agents, such as antibodies with the potency of alpha-particle emitting radioisotopes to specifically attack and eradicate cancer cells.” The company is a spinout from McMaster University in Ontario. “Targeted delivery of medical isotopes that emit alpha particles can be used to kill tumor cells with remarkable precision and unprecedented potency, and it has the added potential of having complementary effects with treatments which activate the immune system,” said Dr. John Valliant, CEO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.